Scarica l'app Stockscreener
11.20
2.38%
0.26
Dopo l'orario di chiusura:
11.23
0.03
+0.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RCEL Giù?
Forum
Previsione
Frazionamento azionario
Avita Medical Inc Borsa (RCEL) Ultime notizie
Precision Trading with Avita Medical Inc. (RCEL) Risk Zones - Stock Traders Daily
564,952 Shares in Avita Medical Inc. $RCEL Bought by BlackRock Inc. - MarketBeat
RCEL stock gains on fresh price data while Avita Medical readies next steps - AD HOC NEWS
Gross margin % of AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs – HAM:51KB - tradingview.com
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference - Investing News Network
AVITA Medical to Showcase Leadership at Lake Street and Morgan Stanley Healthcare Conferences in September 2026 - Kalkine Media
AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs Balance Sheet – HAM:51KB - tradingview.com
51KB Stock Price and Chart — HAM:51KB - tradingview.com
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy - finance.yahoo.com
Avita Medical Inc.ADR Peer Comparison – Compare with Others - Value Research
Lake Street Maintains Avita Medical(RCEL.US) With Buy Rating, Raises Target Price to $12 - Moomoo
RCEL | Avita Medical, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases - finance.yahoo.com
AVITA Medical: Favorable Reimbursements For Skin Wound Care (NASDAQ:RCEL) - Seeking Alpha
Avita Medical (RCEL) Stock Forum and Discussion - Moomoo
RCEL Maintained by TD Cowen -- Price Target Raised to $14.00 - GuruFocus
TD Cowen raises Avita Medical stock price target on PermeaDerm data - Investing.com Canada
RCEL Maintained by BTIG -- Price Target Raised to $11.00 - GuruFocus
AVITA Medical (NASDAQ:RCEL) Raises Full-Year Guidance on Spray-On Skin Adoption - Kalkine Media
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BTIG raises Avita Medical stock price target on positive trial data - Investing.com Canada
TD Cowen Maintains Avita Medical(RCEL.US) With Buy Rating, Raises Target Price to $14 - Moomoo
AVITA Medical Reveals PermeaDerm Trial Results: 70% Cost Reduction Compared to Allograft - Kalkine Media
Avita Medical Inc. (NASDAQ:RCEL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
AVITA Medical (ASX:AVH) Jumps 23.18% as Shares Extend a 67% One-Year Recovery - Kalkine
AVITA Medical (ASX:AVH) Soars 22.73% as Revenue Upgrade and Cash-Flow Target Reset the Conversation - Kalkine
AVITA Medical (ASX: AVH) Reports 70% Cost Advantage for PermeaDerm in Randomized Study - Kalkine
Avita Medical Says Clinical Study for Biosynthetic Wound Matrix Meets Primary Endpoint - marketscreener.com
AVITA Medical's PermeaDerm-I Study Reveals 70% Cost Savings Over Cadaveric Allograft with Equivalent Clinical Results - Kalkine Media
AVITA Medical Inc to Host Key Opinion Leader Webinar Transcript - GuruFocus
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes - Investing News Network
RCEL Looks 21.8% Undervalued on GF Value™ - GuruFocus
Avita Medical Says PermeaDerm Study Meets Primary Endpoint, Showing 70% Cost Reduction - marketscreener.com
AVITA Medical’s PermeaDerm shows 70% cost savings over allograft By Investing.com - Investing.com Canada
A wound matrix cut prep time 96% with outcomes comparable to cadaver grafts - Stock Titan
Avita Medical Raises Full Year 2026 Revenue Guidance - sekbernews.id
Avita Medical Raises Revenue Guidance and Targets Breakeven - sekbernews.id
AVITA Medical Inc Annual Shareholders Meeting Transcript - GuruFocus
RCEL Q2 2026 Earnings: Narrower Quarterly Loss Beats Estimates; Shares Slip 2%Earnings Quality Analysis - Vinanet
AVITA Medical, Inc. (RCEL) Shareholder/Analyst CallSlideshow (NASDAQ:RCEL) 2026-08-16 - Seeking Alpha
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18% - MarketBeat
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds - MarketBeat
RCEL Q2 2026 Earnings: EPS Beat of 14.5% Overshadowed by a 2% Stock DeclineEarnings Expansion Phase - Vinanet
RCEL Q2 2026 Earnings: Loss Narrower Than Expected, Delivering 14.5% EPS SurpriseSpecial Dividend Alert - Vinanet
RCEL Q2 2026 Earnings: Narrower Loss Beats Expectations as Shares Edge LowerEstimate Revision Count - Vinanet
AVITA Medical Inc (RCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript - AOL.com
Avita Medical (RCEL) Rises 3.57% as Shares Rebound Toward Key ResistanceStock Surge Alerts - vinanet.vn
Avita Medical (RCEL) Dips to $8.12 as Support at $7.71 Moves into FocusPCR Extreme - vinanet.vn
Avita Medical Inc. (ASX:AVH) Share Price Remains Unchanged as Stock Trades Within Daily Range - Kalkine
AVITA Medical at canaccord growth conference: growth resumes By Investing.com - Investing.com Canada
AVITA Medical Inc (ASX:AVH) Shares Reach 52-Week High at AUD 2.30 - Kalkine
Avita Medical Issues 7,260 Restricted US Stock Units to Key Management Personnel - Kalkine
Form 8K Avita Medical Ltd For: 11 August By Investing.com - Investing.com Nigeria
Avita Medical amends agreement with Stedical Scientific to expand distribution rights - Investing.com Nigeria
Avita Medical Inc. (ASX:AVH) Share Market Overview and Biotechnology Sector Profile - Kalkine
Avita Medical Target Price Raised 52% to A$1.90/Share by Canaccord Genuity>AVH.AU - Moomoo
Avita Medical Company Profile & Introduction - Moomoo
AVITA Medical to Host Investor Webinar Briefing on 12 August 2026 - Kalkine
0.86%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):